HORIZON (OP-106) study of melflufen in patients with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab and/or pomalidomide: Updated efficacy and safety Meeting Abstract
| Authors: | Richardson, P. G.; Oriol, A.; Larocca, A.; Otero, P. R.; Norkin, M.; Bladé, J.; Cavo, M.; Hassoun, H.; Leleu, X.; Alegre, A.; Maisel, C.; Paner, A.; Mazumder, A.; Zonder, J. A.; Puig, N.; Harran, J.; Harmenberg, J.; Thuresson, S.; Zubair, H.; Mateos, M. V. |
| Abstract Title: | HORIZON (OP-106) study of melflufen in patients with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab and/or pomalidomide: Updated efficacy and safety |
| Meeting Title: | 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019) |
| Keywords: | multiple myeloma; phase 2; pomalidomide; mm; daratumumab; melflufen |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 19 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 11-14 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-09-01 |
| Start Page: | S329 |
| End Page: | S330 |
| Language: | English |
| ACCESSION: | WOS:000483480700351 |
| DOI: | 10.1016/j.clml.2019.07.318 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: MM-250 -- Source: Wos |
